Innate Pharma Financials - Benzinga

Innate Pharma SA

IPHANASDAQ

Trade with Public

Trade with Public

$2.54

0.0652.63%

At close: Aug 12, 5:00 PM EST

$2.15

-0.32-12.96%

Pre-Market: 8:13 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Innate Pharma Financials

Innate Pharma (IPHA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Earnings Scheduled For March 26, 2026

Benzinga Insights

PRO
Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 1.69 percent increase over losses of $(0.65) per share from the

Benzinga Newsdesk

Earnings Scheduled For September 17, 2025

Benzinga Insights

PRO
Innate Pharma H1 EPS $(0.28) Up From $(0.34) YoY, Sales $5.51M Down From $13.35M YoY

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent increase over losses of $(0.34) per share from the same period last year. The company reported $5.51 million in sales

Benzinga Newsdesk

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Vandana Singh

Earnings Scheduled For March 27, 2025

Benzinga Insights